

Maja Đanić (rođ. Stojančević)

Datum rođenja 27.03.1987.
Mesto rođenja Sombor, RS
E-mail maja.djanic@mf.uns.ac.rs



OBRAZOVANJE

- Okt 2019.- danas Zdravstvena specijalizacija iz oblasti Kliničke Farmacije (Medicinski fakultet, Univerzitet u Novom Sadu)
2010. - 2016. Doktorske studije, smer Klinička medicina, Medicinski fakultet, Univerzitet u Novom Sadu
- Zvanje: **doktor medicinskih nauka - farmacija**
 - Prosečna ocena: 10,00
 - Naziv teze: *Uticaj soli žučnih kiselina na prodor i metabolizam simvastatina u probiotskim bakterijama*; mentor: prof. dr Momir Mikov
2005. - 2010. Integrisane akademske studije farmacije, Medicinski fakultet, Univerzitet u Novom Sadu
- Zvanje: **diplomirani farmaceut - master**
 - Prosečna ocena: 9,70
 - Tema diplomskog rada: *Određivanje ukupnih fenola i antioksidativne aktivnosti u medu različitog porekla*; mentor: prof. dr Jelena Cvejić
- 2001.-2005. Gimnazija Veljko Petrović, Sombor (prirodno-matematički smer)

RADNO ISKUSTVO

- Jun 2017. - danas
- **Asistent sa doktoratom** na Katedri za farmakologiju i toksikologiju na Medicinskom fakultetu u Novom Sadu
- Feb 2011. - jun 2017.
- Angažovana na projektu Ministarstva prosvete, nauke i tehnološkog razvoja na Katedri za farmakologiju i toksikologiju Medicinskog fakulteta u Novom Sadu, prvo kao **stipendista Ministarstva** prosvete, nauke i tehnološkog razvoja, a potom kao **istraživač-saradnik**
 - Istraživanja iz oblasti metabolizma lekova pod dejstvom crevne mikroflore kao i ispitivanja žučnih kiselina kao modifikatora prolaska lekova kroz biološke membrane.
 - Izvođenje praktične nastave na Katedri za farmakologiju i toksikologiju na Medicinskom fakultetu u Novom Sadu iz predmeta *Opšta Farmakologija* na studijskim smerovima medicina, farmacija i stomatologija i iz predmeta *Farmakologija i toksikologija* na smerovima zdravstvena nega i medicinska rehabilitacija
- Okt 2011. - okt 2012.
- Pripravnički staž za diplomirane farmaceute, apoteka Irisfarm (položen stručni ispit za diplomirane farmaceute)

NAGRADE I STIPENDIJE

- Nov 2020 ▪ Nominacija za *International Medis Awards 2020 for Medical Research*
- Sep 2020 ▪ Nagrada najboljim nastavnicima Medicinskog Fakulteta za objavljivanje radova u renomiranim svetskim časopisima za 2019. godinu
- Maj 2019 ▪ Nagrada najboljim nastavnicima Medicinskog Fakulteta za objavljivanje radova u renomiranim svetskim časopisima za 2018. godinu
- Mart 2018 ▪ Nagrada najboljim nastavnicima Medicinskog fakulteta za učešće na prvoj zajedničkoj konferenciji Medicinskog fakulteta Novi Sad, Univerziteta u Novom Sadu i Medicinskog fakulteta, Univerziteta Prince of Songkla, Hat Yai, Tajland
- Maj 2017. ▪ Nagrada Fonda za najdarovitije studente doktorskih studija Medicinskog fakulteta Univerziteta u Novom Sadu za školsku 2016/2017. godinu
- Maj 2014. ▪ Stipendija i poziv za predavanje međunarodnog udruženja o probioticima na *4. International Probiotic Congress* u Atini, Grčka
- Sep 2012. ▪ Stipendija Austrijskog Farmakološkog društva za učešće na *18. APHAR kongresu* u Gracu, Austrija
- Feb 2011. - nov 2012. ▪ Stipendija Ministarstva Prosvete, Nauke i Tehnološkog razvoja najboljim studentima doktorskih studija u Srbiji
- Okt 2009. - okt 2010. ▪ Stipendija Republičke Fondacije za razvoj naučnog i umetničkog podmlatka
- Okt 2009. ▪ Stipendija Fonda za stipendiranje darovitih studenata Univerziteta u Novom Sadu
- 2006. - 2010. ▪ Nagrade Univerziteta u Novom Sadu za postignut uspeh tokom studija (za 2005/2006, 2006/2007. 2009/2010 školsku godinu)
- 2005. - 2010. ▪ Stipendija Somborske opštine, fond Laza Kostić, izuzetna nagrada za najbolje maturante opštine Sombor

STRUČNA DOSTIGNUĆA

- Autor 17 radova u referentnim međunarodnim časopisima indeksiranim u *Web of Science* (SCI lista) (2 rada u časopisu M21a, 4 u M21, 2 u M22 i 9 u časopisima M23 kategorije, u 9 radova prvi autor)
- Autor 13 radova u časopisima nacionalnog značaja
- Autor 79 saopštenja sa međunarodnih skupova i 39 saopštenja sa skupova nacionalnog značaja
- Predavanje po pozivu sa međunarodnog skupa o probioticima štampano u izvodu
- Predavanje po pozivu na 3. letnjoj školi evropskog društva farmakogenomike i personalizovane terapije (ESPT)
- Koautor monografije nacionalnog značaja pod nazivom „*Interpretacija najčešćih laboratorijskih analiza i uticaj lekova na njih*“
- Koautor 2 poglavlja u monografijama nacionalnog značaja
- Član uređivačkog odbora knjige *Lekovi u prometu* od 2012. godine
- Indeks kompetentnosti: **184.4**
- *h-index* : Google Scholar – **11**; Scopus – **9**; Citiranost: Google Scholar – **428**; Scopus – **289**
- Recenzent u časopisima *Pharmacological Research*, *Pharmaceutical Development and Technology*, *European Journal of Inflammation*
- Član srpskog farmakološkog društva

- Član organizacionog odbora 14. Kongresa Farmakologa Srbije i 4. Kongresa kliničke farmakologije sa međunarodnim učešćem (18.9-19.9.2019., Novi Sad, Srbija) kao i predstojećeg JCMST kongresa
- Učešće na nacionalnom i internacionalnom kongresu studenata biomedicinskih nauka kao član komisije (2019)
- Mentorstvo u tri naučna studentska rada izložena na nacionalnom i internacionalnom kongresu studenata biomedicinskih nauka (2018 i 2019. godine)

USAVRŠAVANJA

- | | |
|-----------|--|
| Okt 2017 | ▪ <i>TRAIN (Training and Research for Academic Newcomers - projekat usavršavanja akademskog osoblja) - Priprema projektnih aplikacija i menadžment projekata, Univerzitet u Novom Sadu</i> |
| Okt 2017 | ▪ <i>MEDLEM Letnja škola - Microfluidic chips fabrication and application in pharmacokinetics based on fractional models (Fakultet za Tehničke nauke Novi Sad)</i> |
| Mar 2017 | ▪ <i>FOODstars Workshop: Green extraction techniques in food science u Novom Sadu u organizaciji Univerziteta u Lajdenu, Holandija na čelu sa Dr Young Hae Choi i Naučnog instituta za prehrambene tehnologije u Novom Sadu (sertifikat)</i> |
| Avg 2016 | ▪ <i>3. Letnja škola evropskog društva farmakogenomike i personalizovane terapije (ESPT) u Beogradu (sertifikat o učešću i održanom predavanju)</i> |
| Jun 2013. | ▪ <i>8. Međunarodna škola masene spektrometrije - The mass spectrometry in environmental and biochemical analysis u Nišu u organizaciji Prirodno-matematičkog fakulteta u Nišu i Univerziteta Pjer i Marija Kiri u Parizu (sertifikat)</i> |
| Apr 2013. | ▪ <i>Seminar Agilent consumables will make your lab bloom, Novi Sad u organizaciji DSP chromatography (sertifikat)</i> |
| Feb 2012. | ▪ <i>Kurs Priprema IPA prekograničnih projekata u organizaciji Fonda „Evropski poslovi“ AP Vojvodine (sertifikat)</i> |

UČEŠĆE U NAUČNO-ISTRAŽIVAČKIM PROJEKTIMA

- | | |
|---------------|--|
| 2011. - danas | ▪ <i>Projekat finansiran od strane Ministarstva prosvete, nauke i tehnološkog razvoja Republike Srbije: „Interakcije ksenobiotika i njihov uticaj na sisteme u biomedicini“, broj 41012, rukovodilac projekta prof. dr Momir Mikov</i> |
| 2016. – 2020. | ▪ <i>Dugoročni projekat finansiran od strane Pokrajinskog sekretarijata za nauku i tehnološki razvoj AP Vojvodine: „Optimizacija farmakokinetike metotreksata radi individualizacije lečenja leukemije primenom frakcionog računa i mikrofluidnog elektronskog uređaja“, rukovodilac projekta prof. dr Momir Mikov</i> |

NAUČNO-ISTRAŽIVAČKI RAD

- | | |
|----------------------|--|
| Oblasti istraživanja | <ul style="list-style-type: none"> ▪ Crevna mikroflora i probiotici u metabolizmu lekova ▪ Transport lekova kroz biološke membrane ▪ Žučne kiseline kao modifikatori prolaska lekova kroz biološke membrane ▪ Žučne kiseline i nuklearni receptori |
| Analitičke tehnike | <ul style="list-style-type: none"> ▪ UV/VIS spektrofotometrija ▪ visoko efikasna tečna hromatografija (HPLC) ▪ tečna hromatografija sa masenom spektrometrijom (LC-MS/MS) |

Softveri u naučno-
istraživačkom radu

- ChemBioOffice 12.0 (Cambridge Soft, Cambridge, MA, USA)
- VolSurf+ (Molecular Discovery Ltd, London, UK)
- OriginPro 8.5 (OriginLab Software, Northampton, MA, USA)
- SPSS Statistics 19.0 (SPSS Inc., Chicago, IL, USA)

OSTALO

Strani jezici

- engleski (napredni nivo)
- nemački (osnovni nivo - položen DAAD kurs)

<https://scholar.google.com/citations?user=easRsy8AAAAJ&hl=en>

Linkovi

<https://orcid.org/0000-0002-7785-0666>

https://www.researchgate.net/profile/Maja_Danic_stojancevic

<http://knr.uns.ac.rs/knrPublic.xhtml> (ID 4220)

BIBLIOGRAFIJA

M21a - RAD U MEĐUNARODNOM ČASOPISU IZUZETNIH VREDNOSTI

1. Lazarević S, **Đanić M**, Goločorbin Kon S, Al-Salami H, Mikov M. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. *Pharmacol Res.* 2019 Jun 26:104333. doi: 10.1016/j.phrs.2019.104333. (IF 2018-5.574)
2. **Stojančević M**, Bojić G, Al-Salami H, Mikov M. The Influence of Intestinal Tract and Probiotics on the Fate of Orally Administered Drugs. *Curr Issues Mol Biol.* 2013;16(2):55-68. (IF 2014-5.75)

M21- RAD U VRHUNSKOM MEĐUNARODNOM ČASOPISU

1. **Đanić M**, Stanimirov B, Pavlović N, Vukmirović S, Lazić J, Al-Salami H, Mikov M. Transport and biotransformation of gliclazide and the effect of deoxycholic acid in a probiotic bacteria model. *Front Pharmacol.* 2019; doi: 10.3389/fphar.2019.01083 (in press) (IF 2018-3.845)
2. **Đanić M**, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. *Front Pharm.* 2018. Doi: 10.3389/fphar.2018.01382 (IF 2018-3.845)
3. Pavlović N, Goločorbin-Kon S, **Đanić M**, Stanimirov B, Al-Salami H, Stankov K, Mikov M. Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. *Front Pharmacol.*, 2018; 9(1283):doi.org/10.3389/fphar.2018.01283 (IF 2018-3.845)
4. **Stojančević M**, Pavlović N, Goločorbin-Kon S, Mikov M. Application of bile acids in drug formulation and delivery. *Front Life Sci (HFSP Journal).* 2013; 7(3-4):112-22. (IF 2012-1.471)

M22 - RAD U ISTAKNUTOM MEĐUNARODNOM ČASOPISU

1. Pavlović N, **Đanić M**, Stanimirov B, Goločorbin-Kon S, Stankov K, Lalić-Popović M, Mikov M. In Silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders. *Curr Pharm Des.* 2019;25: 1-8 DOI: 10.2174/1381612825666191029095252
2. **Đanić (Stojančević) M**, Pavlović N, Stanimirov B, Vukmirović S, Nikolić K, Agbaba D, Mikov M. The influence of bile salts on the distribution of simvastatin in octanol/buffer system. *Drug Dev Ind Pharm.* 2016;42(4):661-7. (IF 2016- 2.295)

M23 - RAD U MEĐUNARODNOM ČASOPISU

1. Mikov M, Pavlović N, Stanimirov B, **Đanić M**, Goločorbin-Kon S, Stankov K, Al-Salami H. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. *Eur J Drug Metab Pharmacokinet.* 2019 Aug 5. doi: 10.1007/s13318-019-00570-y. (IF 2018-1.497)
2. Mikov M, **Đanić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Stankov K, Al-Salami H. Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. *Eur J Drug Metab Pharmacokinet.* 2018 Jun;43(3):269-280. doi: 10.1007/s13318-017-0441-y. (IF 2018-1.497)
3. Mikov M, **Đanić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Stankov K. The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. *Eur J Drug Metab Pharmacokinet.* 2017;42(6):881-890. doi:10.1007/s13318-017-0417-y. (IF 2017-1.362)
4. **Đanić M**, Pavlović N, Stanimirov B, Stojančević T, Goločorbin-Kon S, Bojić G, Mikov M. Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria. *Eur Rev Med Pharmacol.* 2016;20(3):553-60. (IF 2016-1.778)
5. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, **Stojančević M**, Golocorbin-Kon S, Al-Salami H. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. *Pharm Dev Technol.* 2015;20(6):702-9. (IF 2015-1.566)
6. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, Mikov M, Lalic-Popovic M, **Stojančević M**, Golocorbin-Kon S, Al-Salami H. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. *J Pharm Innov.* 2014;9:150-7. (IF 2014-0.718)
7. Bojić G, Milošević V, Gusman V, Považan A, **Stojančević M**. The contribution of gut microflora

to paracetamol metabolism. *Arch Biol Sci.* 2014; 66(1): 75-8. (IF 2014-0.622)

8. Pavlović N, Stanimirov B, **Stojančević M**, Paut-Kusturica M, Stoimenova A, Goločorbin-Kon S, Mikov M. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. *Biotechnol & Biotechnol Eq.* 2012; 26(5): 3236-41. (IF 2012-0.622)
9. **Stojančević M**, Stankov K, Mikov M. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. *Can J Gastroenterol.* 2012; 26(9): 631-7. (IF 2012-1.532)

M32 - PREDAVANJE PO POZIVU SA MEĐUNARODNOG SKUPA ŠTAMPANO U IZVODU

1. Mikov M, **Đanić M**, Goločorbin-Kon S, Pavlović N, Stanimirov B, Stankov K. The gut microbiome in personalized medicine. 3rd ESPT Summer School, Belgrade, Serbia: August 20-25, 2016.
2. **Stojančević M**, Pavlović N, Stanimirov B, Mikov M. The influence of gut microflora on drug metabolism. *Beneficial Microbes.* 2014; 5(Suppl 1):S21. 4th IPA World Congress. Athens, Greece: May 9-11, 2014.

M33-SAOPŠTENJE SA MEĐUNARODNOG SKUPA ŠTAMPANO U CELINI

1. Goločorbin-Kon S, Lalić-Popović M, Pavlović N, **Đanić M**, Cvejić J, Ilić V, Mikov M. The approach to the pharmaceutical waste management in the world and in Serbia. 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5 2016. pp. 95-96.
2. **Đanić M**, Pavlović N, Lalić-Popović M, Stanimirov B, Goločorbin-Kon S, Stankov K, Mikov M. In vitro model for the analysis of 12-monoketocholate impact on simvastatin physico-chemical behavior in octanol/buffer system. 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5, 2016. pp. 393-394.
3. Goločorbin-Kon S, Pavlović N, **Đanić M**, Lalić-Popović M, Gigov S, Jojić N, Mikov M. Is cannabis addictive? 6th Congress on pharmacy of Macedonia with international participation. Abstract book, Ohrid, Macedonia: June 1-5, 2016. pp. 471-472.
4. Stanimirov B, Pavlović N, Stankov K, **Đanić M**, Kojić V, Goločorbin-Kon S, Mikov M. May bile acids be utilized to enrich oncological armamentarium? 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5, 2016. pp. 563-564.
5. **Đanić M**, Pavlović N, Stanimirov B, Stojančević T, Goločorbin-Kon S, Mikov M. Prediction of binding affinities of different bile acids towards multidrug transporters in *Lactobacillus acidophilus* NCFM: a pharmacoinformatic approach. 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5, 2016. pp. 565-566.
6. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Goločorbin-Kon S, Mikov M. Targeting endoplasmic reticulum stress in diabetes. 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5, 2016. pp. 579-580.
7. Lalić-Popović M, Goločorbin-Kon S, **Đanić M**, Milošević N, Vasović N, Milijašević B, Mikov M. Distribution coefficient of gliclazide as in vitro prediction model of blood brain barrier penetration. 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5, 2016. pp. 375-376.
8. Goločorbin-Kon S, Lalić-Popović M, Pavlović N, **Đanić M**, Milošević N, Rakić B, Mikov M. The use of drugs outside of approved application. 6th Congress on pharmacy of Macedonia with international participation. Ohrid, Macedonia: June 1-5, 2016. pp. 69-70.

M34 - SAOPŠTENJE SA MEĐUNARODNOG SKUPA ŠTAMPANO U IZVODU

1. Pavlović N, Stankov K, Goločorbin-Kon S, Lalić-Popović M, Todorović N, **Đanić M**, Mikov M. Can bile acids be safely used as pharmaceutical excipients? 8th BBBB International Conference on Pharmaceutical Sciences. Izmir, Turkey: October 14-16, 2019. Pp. 212-213.
2. **Đanić M**, Pavlović N, Stanimirov B, Lazarević S, Goločorbin-Kon S, Smieško G, Mikov M. Gut microflora affects therapeutic effects of drugs. 3rd Congress of Pharmacists of Montenegro with international participation. Bečići, Montenegro: May 9-12, 2019. pp. 126-127.
3. Goločorbin-Kon S, Pavlović N, Vukmirović S, **Đanić M**, Milijašević B, Paut Kusturica M, Tomas

- A, Stanimirov B, Al-Salami H, Mikov M. New pharmaceutical formulations and new indications for an old drug – methotrexate. 3rd Congress of Pharmacists of Montenegro with international participation. Bečići, Montenegro: May 9-12, 2019. pp. 146-147.
4. Goločorbin-Kon S, Pavlović N, Vukmirović S, Lalic-Popovic M, Milosevic N, Jovicic-Bata J, Gavaric N, **Đanić M**, Todorovic N, Mikov M. Botulinum toxin – poison, medicine and cosmetic preparation. 3rd Congress of Pharmacists of Montenegro with international participation. Bečići, Montenegro: May 9-12, 2019. pp. 148-149.
 5. Pavlović N, Goločorbin-Kon S, Stankov K, **Đanić M**, Stanimirov B, Lalić-Popović M, Mikov M. In silico alternatives to animal testing: state of the art. 3rd Congress of Pharmacists of Montenegro with international participation. Bečići, Montenegro: May 9-12, 2019. pp. 185-186.
 6. Pavlović N, Goločorbin-Kon S, Stankov K, **Đanić M**, Stanimirov B, Lalić-Popović M, Mikov M. Development of carnosol analogues with improved pharmacokinetic and toxicological properties: pharmacoinformatics study. 3rd Congress of Pharmacists of Montenegro with international participation. Bečići, Montenegro: May 9-12, 2019. pp. 186-187.
 7. Pavlović N, Stankov K, Goločorbin-Kon S, Lalić-Popović M, Stanimirov B, **Đanić M**, Mikov M. Non-toxic bile acids as pharmaceutical excipients may alter pharmacological activity of antitumor drug vorinostat. 12th Central European Symposium on Pharmaceutical Technology and Regulatory Affairs. Segedin, Hungary: September 20-22, 2018. pp.204-204.
 8. **Đanić M**, Stanimirov B, Pavlović N, Goločorbin-Kon S, Mikov M. Transport and biotransformation of gliclazide in probiotic bacteria. 12th Central European Symposium on Pharmaceutical Technology and Regulatory Affairs. Segedin, Hungary: September 20-22, 2018. pp.203-204.
 9. Pavlovic N, Stankov K, Stanimirov B, **Djanic M**, Bogdanovic G, Golocorbin-Kon S, Mikov M. Ursodeoxycholic acid modulates intracellular redox state and sensitizes colon cancer cells to the cytotoxicity induced by epigenetic agent vorinostat. 54th Congress of the European Societies of Toxicology (EUROTOX 2018). Brussels, Belgium. September 2-5, 2018. Toxicology Letters. 2018;295(S1):P06-09.
 10. Stanimirov B, Stankov K, Pavlovic N, **Djanic M**, Goločorbin Kon S, Mikov M. *In vivo* effects of ursodeoxycholic acid on doxorubicin-induced oxidative injury of hepatocyte. 18th World Congress of Basic and Clinical Pharmacology (WCP2018). Kyoto, Japan: July 1-6, 2018. p.P01-9-11.
 11. **Đanić M**, Stanimirov B, Pavlović N, Lazarević S, Goločorbin Kon S, Mikov M. Preliminary study on gliclazide–probiotic bacteria interactions in in vitro conditions. Intrinsic Activity. 2018;6 (Suppl. 1):A5.7. 24th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 27-28, 2018.
 12. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Katanić J, Barjaktarović I and Mikov M. 12-Oxo-chenodeoxycholic acid potentiates doxorubicin-induced oxidative stress through Nrf2 axis in breast adenocarcinoma cells. Intrinsic Activity. 2018; 6(Suppl. 1):A4.4. 24th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 27-28, 2018.
 13. Lazarević S, **Đanić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S and Mikov M. 12-Monoketocholate: a new perspective in metabolic syndrome treatment. Intrinsic Activity. 2018; 6(Suppl. 1):A1.6. 24th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 27-28, 2018.
 14. **Đanić M**, Pavlović N, Vukmirović S, Stanimirov B, Bojić G, Goločorbin-Kon S, Mikov M. Qualitative analysis of simvastatin metabolites arising from probiotic bacteria - in vitro study. 1st PSU-UNS Joint Conference on Medical Science and Technology, Thailand, Krabi; March 5-7, 2018. Abstract book 2018;67-68.
 15. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Bogdanović G, Kojić V, Mikov M. Bile Acid Potentiates Apoptosis of Human Breast Adenocarcinoma Cells Induced by Doxorubicin. 10th Congress of Toxicology in Developing Countries (CTDC10). Belgrade, Serbia: April 18-21, 2018. Pp.164.
 16. **Đanić M**, Pavlović N, Vukmirović S, Stanimirov B, Stojančević T, Milović M, Mikov M. Preliminary study on probiotic bacteria role in simvastatin activation. 9th PROBIOTICS, PREBIOTICS & NEW FOODS. Rome, Italia: September 10-12, 2017. pp.92
 17. Stojančević T, **Đanić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Bojić G, Mikov M *In silico* prediction of bile acids-drugs interactions at transporter level of Lactobacillus Acidophilus NCFM. 9th PROBIOTICS, PREBIOTICS & NEW FOODS. Rome, Italia: September 10-12, 2017. pp.93
 18. **Đanić M**, Vukmirović S, Pavlović N, Stanimirov B, Goločorbin-Kon S, Mikov M. Bioactivation

- of simvastatin by probiotic bacteria: in vitro study. *Intrinsic Activity*. 2017;5(1):A1.1. 23rd Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 28-29, 2017.
19. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Vasović V, Mikov M. Ursodeoxycholic acid sensitizes human breast adenocarcinoma cells to doxorubicin-induced apoptosis. *Toxicology Letters*. 2017;280S(1):S309–S309. 53rd Congress of the European Societies of Toxicology (EUROTOX). Bratislava, Slovakia: September 10-13, 2017.
 20. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Goločorbin-Kon S, Vasović V, Mikov M. Antioxidant effects of ursodeoxycholic acid in doxorubicin-induced oxidative hepatocyte injury. *Toxicology Letters*. 2017;280S(1):S306–S325. 53rd Congress of the European Societies of Toxicology (EUROTOX). Bratislava, Slovakia: September 10-13, 2017.
 21. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Mikov M. Ursodeoxycholic acid potentiates cytotoxic activity and pro-apoptotic potential of doxorubicin in breast adenocarcinoma cells. 52nd Congress of the European Societies of Toxicology (EUROTOX 2016). Seville, Spain: September 4-7, 2016. *Toxicology Letters*. 2016; 258S: P06-028.
 22. Stanimirov B, Stankov K, Pavlović N, **Djanic M**, Kojic V, Bogdanovic G, Mikov M. Cytotoxic activities and pharmacological interactions of natural bile acids with doxorubicin in human breast adenocarcinoma cell line. *Value in Health* 2016;19(3):A138. 21st ISPOR Annual International Meeting. Washington, USA: May 21-25, 2016.
 23. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Kojić V, Barjaktarović I, Mikov M. The effects of ursodeoxycholic acid on cytotoxic activity and proapoptotic potential of doxorubicin in MCF-7 cell line. 7th European Congress of Pharmacology (EPHAR 2016). Istanbul, Turkey: June 26-30, 2016. pp. 560.
 24. **Đanić M**, Pavlović N, Stanimirov B, Stankov K, Goločorbin-Kon S, Mikov M. Hypocholesterolemic effect of probiotics. 7th European Congress of Pharmacology (EPHAR 2016). Istanbul, Turkey: June 26-30, 2016. pp. 341.
 25. **Djanic M**, Pavlovic N, Stanimirov B, Vukmirovic S, Mikov M. Cholic Acid Decreases the Distribution Coefficient of Simvastatin: A Potential for Increasing Simvastatin Bioavailability. *Value Health*. 2015 Nov;18(7):A814-5. 5th ISPOR Latin America Conference. Santiago, Chile USA: September 6-8, 2015.
 26. **Đanić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Mikov M. Probiotics: alternative or complementary therapy for hypercholesterolemia. 4th International Symposium on Adipobiology and Adipopharmacology. Bucharest, Romania: October 28-31, 2015. p.1.8
 27. Pavlović N, Stankov K, Stanimirov B, **Đanić M**, Mikov M. The potential role of epigenetic agents in regulation of lipid metabolism. 4th International Symposium on Adipobiology and Adipopharmacology. Bucharest, Romania: October 28-31, 2015. p.2.2
 28. Stanimirov B, Stankov K, Pavlovic N, **Djanic M**, Mikov M. Liporegulatory effects of bile acid receptor – farnesoid x receptor. 4th International Symposium on Adipobiology and Adipopharmacology. Bucharest, Romania: October 28-31, 2015. p.2.9
 29. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Kojić V, Bogdanović G, Mikov M. Epimer-specific effects of bile acids on the anti-neoplastic activity of doxorubicin in MCF-7 breast adenocarcinoma cells. FEBS3+Meeting Molecules of Life. Portorož, Slovenia: September 16-19, 2015. pp.223.
 30. **Đanić M**, Pavlović N, Stanimirov B, Goločorbin Kon S, Mikov M. The role of bile acids in drug penetration through biological membranes. *Intrinsic Activity*. 2015;3 (Suppl. 2):A7.5. 21st Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 16-18, 2015.
 31. Pavlović N, Stankov K, Stanimirov B, **Đanić M**, Kojić V, Bogdanović G, Mikov M. The influence of pretreatment with antioxidants on cytotoxicity of the epigenetic agent vorinostat towards HT-29 colon cancer cells. *Intrinsic Activity*. 2015;3 (Suppl. 2):A5.3. 21st Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 16-18, 2015.
 32. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Kojić V, Salatić I, Mikov M. Transcriptomic

- effects of ursodeoxycholic acid treatment on adriamycin-induced oxidative liver injury. *Intrinsic Activity*. 2015;3 (Suppl. 2):A6.3. 21st Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 16-18, 2015.
33. Jelić M, Pavlović N, Jojić N, Stankov K, Stanimirov B, **Đanić M**, Mikov M. Oxresveratrol as a promising drug candidate for metabolic diseases: a pharmacoinformatics study. *Intrinsic Activity*. 2015;3 (Suppl. 2):A7.4. 21st Scientific Symposium of the Austrian Pharmacological Society (APHAR) Graz, Austria: September 16-18, 2015.
 34. Pavlović N, Stankov K, Stanimirov B, **Đanić M**, Mikov M. Glutathione-dependent pathways in anti-cholestatic activity of chenodeoxycholic acid. *International Workshop on Biochemistry, Physiology and Pharmacology of Oxidative Stress*. Rome, Italy: July 2-4, 2015. p. 42.
 35. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Mikov M. Transcriptomic analysis of ursodeoxycholic acid administration effects on adriamycin-induced oxidative stress in liver. *International Workshop on Biochemistry, Physiology and Pharmacology of Oxidative Stress*. Rome, Italy: July 2-4, 2015. p. 57.
 36. **Đanić M**, Pavlović N, Stanimirov B, Mikov M. Antioxidative potential of probiotics in inflammatory bowel disease. *International Workshop on Biochemistry, Physiology and Pharmacology of Oxidative Stress*. Rome, Italy: July 2-4, 2015. p. 14.
 37. Pavlović N, Stankov K, Stanimirov B, **Đanić M**, Kojić V, Bogdanović G, Mikov M. Epimer specific effects of bile acids on HT-29 colon cancer cells proliferation. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 164-165.
 38. Pavlović N, Stankov K, Stanimirov B, **Đanić M**, Goločorbin-Kon S, Mikov M. Comparative study on effects of chenodeoxycholic acid and ursodeoxycholic acid on serum biochemical parameters in cholestatic rats. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 162-163.
 39. Pavlović N, Jojić N, Stankov K, Stanimirov B, **Đanić M**, Mikov M. In silico discovery of resveratrol analogues as potential agents in therapy of metabolic diseases. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 131-132.
 40. **Đanić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Mikov M. The affinities of different bile acids towards multidrug transporters in *Bifidobacterium longum* NCC2705. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 114-115.
 41. **Đanić M**, Pavlović N, Stanimirov B, Vukmirović S, Goločorbin-Kon S, Mikov M. The influence of deoxycholic acid on the distribution coefficient of simvastatin. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 116-117.
 42. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Vukmirović S, Goločorbin-Kon S, Mikov M. Ursodeoxycholic acid reduces doxorubicin-induced oxidative stress in the liver. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 172-173.
 43. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Vukmirović S, Goločorbin-Kon S, Mikov M. Bile acids in the therapy of metabolic diseases. *2nd Congress of Pharmacists of Montenegro with international participation*. Bečići, Montenegro: May 28-31, 2015. pp. 174-175.
 44. Stanimirov B, Stankov K, Pavlović N, **Stojančević M**, Vukmirović S, Mikov M. The amelioration of doxorubicin-induced oxidative liver injury by ursodeoxycholic acid. *Value in Health*. 2015; 18(3):222. 19th ISPOR Annual International Meeting. Philadelphia, USA: May 16-20, 2015.
 45. Pavlović N, Stankov K, Stanimirov B, **Stojančević M**, Kojić V, Bogdanović G, Mikov M. Ursodeoxycholic and chenodeoxycholic acid exert distinct cytotoxic effects on colon cancer cells. *Value in Health*. 2015; 18(3):192. 19th ISPOR Annual International Meeting. Philadelphia, USA: May 16-20, 2015.
 46. **Stojančević M**, Stanimirov B, Pavlović N, Al-Salami H, Goločorbin-Kon S, Mikov M. The influence of the intestinal environment in drug bioavailability. *Intrinsic Activity*. 2014; 2(Suppl. 1): A1.6. 20th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Innsbruck, Austria: September 26-27, 2014.

47. Stanimirov B, Stankov K, Pavlović N, **Stojančević M**, Mihajlović D, Stankov S, Mikov M. In vivo analysis of cytotoxic effects of alpha-tocopheryl succinate in Ehrlich ascites carcinoma. *Intrinsic Activity*. 2014; 2(Suppl. 1): A1.3. 20th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Innsbruck, Austria: September 26-27, 2014.
48. Goločorbin-Kon S, Lalić-Popović M, Milošević N, Milić N, Jovičić-Bata J, **Stojančević M**. The role of community pharmacist in health promotion. 48 Days of Preventive Medicine, International Congress. Nis, Serbia: September 23-26, 2014. pp.255.
49. Mikov M., Golocorbin-Kon S., Lalic-Popovic M., **Stojančević M.**, Raskovic A., Vasovic V., Stankov K., Al-Salami H. The effect of bile acid salt sodium 3alpha, 7alpha-dihydroxy-12-keto-5beta-cholanate (MKC) and probiotic pretreatment on gliclazide permeation in ileal tissues from healthy and diabetic rats. *Basic & Clinical Pharmacology & Toxicology*. 2014; 115 (Suppl. 1s), 171-171. 17th World Congress of Basic and Clinical Pharmacology. Cape Town, South Africa: July 13–18, 2014 .
50. **Stojančević M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Al-Salami H, Mikov M. Toxicological consequences of drug metabolism by gut microflora. 11th Serbian Congress of Toxicology. Sremski Karlovci, Serbia: June 24-27, 2014. pp. 25-26.
51. Stanimirov B, Stankov K, Pavlović N, **Stojančević M**, Goločorbin-Kon S, Vukmirović S, Mikov M. The role of redox dyshomeostasis in cardiotoxic effects of doxorubicin. 11th Serbian Congress of Toxicology. Sremski Karlovci, Serbia: June 24-27, 2014. pp. 17-18.
52. Pavlović N, Stankov K, Stanimirov B, **Stojančević M**, Rašković A, Mikov M. Reproductive toxicity of Ginkgo biloba constituents: in silico mechanistic study. 11th Serbian Congress of Toxicology. Sremski Karlovci, Serbia: June 24-27, 2014. pp. 37-38.
53. **Stojančević M**, Paut Kusturica M, Pavlović N, Stanimirov B, Tomić Z, Sabo A, Mikov M. Antidepressants in Serbia and Finland: pharmacoepidemiological study. *Value in Health*. 2013; 16(3): 66-67. 18th ISPOR Annual International Meeting. New Orleans, LA: May 18-22, 2013.
54. Stanimirov B, Pavlović N, **Stojančević M**, Paut Kusturica M, Tomić Z, Sabo A, Mikov M. The comparison of the use of H2-receptor antagonists and proton pump inhibitors between Serbia and Scandinavian countries. *Value in Health*. 2013; 16(3): 298. 18th ISPOR Annual International Meeting. New Orleans, LA: May 18-22, 2013.
55. Pavlović N, Stanimirov B, **Stojančević M**, Paut Kusturica M, Goločorbin-Kon S, Mikov M. Low availability of orphan medicines in Serbia. *Value in Health*. 2013; 16(3): 123-124. 18th ISPOR Annual International Meeting. New Orleans, LA: May 18-22, 2013.
56. Paut Kusturica M, **Stojančević M**, Stanimirov B, Pavlović N. Antibiotics in Serbian home pharmacies. *Value in Health*. 2013; 16(3): 81. 18th ISPOR Annual International Meeting. New Orleans, LA: May 18-22, 2013.
57. **Stojančević M**, Paut Kusturica M, Stanimirov B, Pavlović N, Tomić Z, Sabo A, Mikov M. Remarkably lower consumption of antidepressants in Serbia in comparison with Finland. *BMC Pharmacology and Toxicology*. 2012; 13(Suppl 1): A5. 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 20-21, 2012.
58. Stanimirov B, Stankov K, Pavlović N, Paut Kusturica M, **Stojančević M**, Sabo A, Mikov M. Differences in the use of medicines for peptic ulcer and gastro-esophageal reflux disease between Serbia, Croatia and Sweden. *BMC Pharmacology and Toxicology*. 2012; 13(Suppl 1): A4. 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 20-21, 2012.
59. Pavlović N, Paut Kusturica M, Stanimirov B, **Stojančević M**, Sabo A, Mikov M. Considerable differences in the utilisation of antidiabetics between Serbia and Scandinavian countries. *BMC Pharmacology and Toxicology*. 2012; 13(Suppl 1): A6. 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Graz, Austria: September 20-21, 2012.
60. **Stojančević M**, Paut Kusturica M, Stanimirov B, Pavlović N, Sabo A, Tomić Z, Mikov M. Considerable differences in the utilization of antidepressants between Serbia and Denmark. *Value in Health*. 2012; 15(7): A614. 5th ISPOR Asia-Pacific Conference. Taipei, Taiwan: September 2-4, 2012.
61. Pavlović N, Stanimirov B, **Stojančević M**, Paut Kusturica M, Sabo A, Tomić Z, Mikov M. Consumption of antidiabetics in Serbia in 2010: a comparison with Croatia and Denmark. *Value in*

- Health. 2012; 15(7): A614. 5th ISPOR Asia-Pacific Conference. Taipei, Taiwan: September 2-4, 2012.
62. Stanimirov B, Stankov K, **Stojančević M**, Paut Kusturica M, Pavlović N, Sabo A, Mikov M. Consumption of drugs for peptic ulcer and gastro-esophageal reflux disease: striking differences between Serbia and Norway. Value in Health. 2012; 15(7): A612. 5th ISPOR Asia-Pacific Conference. Taipei, Taiwan: September 2-4, 2012.
 63. **Stojančević M**, Paut Kusturica M, Pavlović N, Stanimirov B, Stankov K, Sabo A, Mikov M. Serbia - the country without depression? Proceedings of the British Pharmacological Society at <http://www.pA2online.org/abstracts/Vol10Issue3abst302P.pdf>. 6th European Congress of Pharmacology (EPHAR 2012). Granada, Spain: July 17-20, 2012.
 64. Paut Kusturica M, **Stojančević M**, Stanimirov B, Pavlović N, Horvat O, Tomić Z, Sabo A. Disposal of unused medications from households in South Backa District, Serbia. Proceedings of the British Pharmacological Society at <http://www.pA2online.org/abstracts/Vol10Issue3abst301P.pdf>. 6th European Congress of Pharmacology (EPHAR 2012). Granada, Spain: July 17-20, 2012.
 65. Stanimirov B, Stankov K, Pavlović N, Paut Kusturica M, **Stojančević M**, Sabo A, Mikov M. Remarkable variations in the use of medicines for peptic ulcer and gastro-esophageal reflux disease between Serbia and the Nordic countries. Proceedings of the British Pharmacological Society at <http://www.pA2online.org/abstracts/Vol10Issue3abst332P.pdf>. 6th European Congress of Pharmacology (EPHAR 2012). Granada, Spain: July 17-20, 2012.
 66. Pavlović N, Stanimirov B, **Stojančević M**, Paut Kusturica M, Stoimenova A, Mikov M. Access to orphan drugs in Serbia: a comparison with Bulgaria and Sweden. 6th European Congress of Pharmacology (EPHAR 2012). Granada, Spain: July 17-20, 2012.
 67. Paut Kusturica M, Sabo A, Stanimirov B, Pavlović N, **Stojančević M**. Is there a difference in antibiotic use between urban and rural communities in Serbia? Abstract book, Euro DURG. Antwerp, Belgium: November 30 - December 3, 2011. p. 49.
 68. Paut Kusturica M, Sabo A, Tomić Z, Pavlović N, **Stojančević M**. Demographic factors influence the amount and structure of drugs in Serbian families. Abstract book, Euro DURG. Antwerp, Belgium: November 30 - December 3, 2011. p. 61.
 69. **Stojančević M**, Stankov K, Mikov M. Potential role of FXR agonists in treatment of IBD. 13th Serbian Congress of Pharmacologists & 3rd Serbian Congress of Clinical Pharmacology with international participation. Palić, Serbia: October 5-8, 2011. pp. 142-143.
 70. Paut Kusturica M, Sabo A, Tomić Z, Pavlović N, Stanimirov B, **Stojančević M**. Is the amount of antibiotics in home pharmacies high? 13th Serbian Congress of Pharmacologists & 3rd Serbian Congress of Clinical Pharmacology with international participation. Palić, Serbia: October 5-8, 2011. pp. 262-263.
 71. **Stojančević M**, Vlajkov N. Correlation of phenolic content and antioxidant capacity of different types of honey. 51. Kongres studenata biomedicinskih nauka Srbije sa internacionalnim učešćem, Ohrid, Makedonija; April 2010. p. 375.

M42 - MONOGRAFIJA NACIONALNOG ZNAČAJA, MONOGRAFSKO IZDANJE GRAĐE

1. Ubavić M, Antonić A, Čabarkapa A, **Đanić M**, Đurković J, Lolić T i sar. Interpretacija najčešćih laboratorijskih analiza i uticaj lekova na njih. Farmaceutski fakultet Novi Sad, Novi Sad, 2017.

M45 - POGLAVLJE U KNJIZI NACIONALNOG ZNAČAJA

1. Mikov M, Stanimirov B, Pavlović N, **Đanić M**, Stankov K. Pretklinička i translaciona faza ispitivanja lekova. U: Kastratović D, Mikov M. Dobra klinička praksa u kliničkim ispitivanjima. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva. 2015 [In Press]
2. Mikov M, Sabo A, Pavlović N, **Stojančević M**, Stanimirov B, Paut Kusturica M. Klinička farmakologija urtikarije. U: Jovanović M, Kristiforović M. Savremeni pristup urtikariji i angioedemu. Akademija medicinskih nauka Srpskog lekarskog društva 2011. Monografije naučnih skupova AMN SLD. 2011; 2(1): 223-252.

M49 - UREĐIVANJE NAUČNE MONOGRAFIJE ILI TEMATSKOG ZBORNIKA

1. Sabo A, Mikov M, Tomić Z (urednici), (**Đanić M**, član uređivačkog odbora, koautor). Lekovi u prometu 2019 (priručnik o lekovima i njihovoj primeni). Novi Sad: Izdavačka knjižarnica Zorana Stojanovića; 2019.
2. Sabo A, Mikov M, Tomić Z (urednici), (**Đanić M**, član uređivačkog odbora, koautor). Lekovi u prometu 2018 (priručnik o lekovima i njihovoj primeni). Novi Sad: Alfagraf; 2018.
3. Sabo A, Mikov M, Tomić Z (urednici), (**Đanić M**, član uređivačkog odbora, koautor). Lekovi u prometu 2017 (priručnik o lekovima i njihovoj primeni). Novi Sad: Alfagraf; 2017.
4. Sabo A, Mikov M, Tomić Z (urednici), (**Đanić M**, član uređivačkog odbora, koautor). Lekovi u prometu 2016 (priručnik o lekovima i njihovoj primeni). Novi Sad: Alfagraf; 2016.
5. Sabo A, Mikov M, Tomić Z (urednici), (**Đanić M**, član uređivačkog odbora, koautor). Lekovi u prometu 2015 (priručnik o lekovima i njihovoj primeni). Novi Sad: Alfagraf; 2015.
6. Sabo A, Mikov M, Tomić Z (urednici), (**Stojančević M**, član uređivačkog odbora, koautor). Lekovi u prometu 2014 (priručnik o lekovima i njihovoj primeni). Novi Sad: Orthomedics; 2014.
7. Sabo A, Mikov M, Tomić Z (urednici), (**Stojančević M**, član uređivačkog odbora, koautor). Lekovi u prometu 2013 (priručnik o lekovima i njihovoj primeni). Novi Sad: Orthomedics; 2013.
8. Sabo A, Mikov M, Tomić Z (urednici), (**Stojančević M**, član uređivačkog odbora, koautor). Lekovi u prometu 2012 (priručnik o lekovima i njihovoj primeni). Novi Sad: Orthomedics; 2012.

M51 - RAD U VODEĆEM ČASOPISU NACIONALNOG ZNAČAJA

1. Smieško G, Mikov M, Gusman V, **Đanić M**. Gut microflora in genesis of methilthyo metabolites of paracetamol. *Zbornik Matice srpske za prirodne nauke*. 2019;137:43-47.
2. Smieško G, Mikov M, Gusman V, **Đanić M**. Urinary tract infections and their importance. *Zbornik Matice srpske za prirodne nauke*. 2019;136(9-21):173-181.
3. Bojić G, Golocorbin Kon S, **Stojančević M**, Mikov M, Suvajdzic Lj. Metabolic activity of gut microbiota and xenobiotics. *Zbornik matice srpske za prirodne nauke*. 2015;128(1):47-55.
4. Kusturica Paut M, **Stojančević M**, Tomić Lj, Tomić Z, Šramka M, Sabo A. Comparison of antidepressant consumption between Serbia and Slovak Republic. *Zdravotništvo A Socijalna Praca*. 2013;4: 5-8.

M52 - RAD U ČASOPISU NACIONALNOG ZNAČAJA

1. Bojić G, Milić S, Mikov M, **Stojančević M**, Golocorbin Kon S, Ugarković J. Problemi u terapiji urinarnih infekcija. *Medicina Danas*. 2015;14(1-3) :16-25.
2. Ugarković J, Bojić G, **Stojančević M**, Mikov M, Golocorbin Kon S, Milić S, Avakumović Reljić K, Suvajdzic Lj. Značaj ispitivanja rezistencije na antimikrobne lekove sojeva bakterija uzročnika urinarnih infekcija. *Medicina Danas*. 2015;14(1-3):26-35.
3. Bojić G, Milić S, Mikov M, **Stojančević M**, Golocorbin Kon S, Ugarković J. Mesto probiotika u sastavu crevne flore. *Medicina Danas*. 2015;14(4-6):65-71.

M53 - RAD U NAUČNOM ČASOPISU

1. Smieško G, Mikov M, Gusman V, Vasović V, Milić S, **Đanić M**. Infekcije urinarnog trakta uzrokovane proteusom. *Medicina danas*. 2019;18(4-6):39-50.
2. Smieško G, Mikov M, Gusman V, Vasović V, Milić S, **Đanić M**. Urinarne infekcije i njihov značaj. 2019;18(7-9):77-86.
3. Smieško G, Mikov M, Gusman V, Vasović V, Milić S, **Đanić M**. Kandida i njen permanentni značaj u infekcijama urinarnog trakta kod ljudi. *Medicina Danas*. 2018;17(1-3):40-49.
4. Smieško G, Mikov M, Gusman V, Vasović V, Milić S, **Đanić M**. Lečenje kandidurije. *Medicina Danas*. 2018;17(4-6):83-94.
5. Smieško G, Mikov M, Gusman V, Vasović V, Milić S, **Đanić M**. Aktuelni uzročnici infekcija urinarnog trakta. *Medicina Danas*. 2018;17(10-12):189-195
6. Mikov M, **Stojančević M**, Bojić G. Probiotics as a promising treatment for inflammatory bowel disease. *Hospital Pharmacology*. 2014; 1(1):52-60.

M64 - SAOPŠTENJE SA SKUPA NACIONALNOG ZNAČAJA ŠTAMPANO U IZVODU

1. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Goločorbin-Kon S, Katanić J, Mikov M. Indukcija mitohondrijalne disfunkcije i stresa endoplazmatskog retikuluma doksorubicinom i 12-

- oksohenodeoksiholnom kiselinom. Simpozijum – XI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar-1. decembar 2019. pp. 80-81.
2. Pavlović N, **Đanić M**, Stanimirov B, Lazarević S, Goločorbin-Kon S, Mikov M Procena inhibitorne aktivnosti metabolita gliklazida nastalih aktivnošću crevne mikroflore prema citohromima P450. Simpozijum – XI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar-1. decembar 2019. pp. 86-87.
 3. Lazarević S, Đanić M, Goločorbin-Kon S, Mikov M. Methotrexate: new research aspects for improved clinical response in childhood acute lymphoblastic leukemia. Simpozijum – XI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar-1. decembar 2019. pp. 90-91.
 4. Mikov M, Vukmirović S, Đanić M, Milijašević B, Stankov K, Goločorbin-Kon S, Al-Salami H. Bile acids as therapeutic agents. Simpozijum – XI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar-1. decembar 2019. pp. 23-24.
 5. Lazarević S, **Đanić M**, Pavlović N, Goločorbin Kon S, Mikov M. Methotrexate' pharmacokinetics elucidation as the key factor in refinement therapy for acute lymphoblastic leukemia. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp 159-160.
 6. Goločorbin Kon S, Pavlović N, **Đanić M**, Lalić-Popović M, Vasović V, Vukmirović S, Teofilović B, Mikov M. Are the clinical pharmacologist and the clinical pharmacist competitors or collaborators? 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 161-162.
 7. Mikov M, Goločorbin-Kon S, Rašković A, Vukmirović S, **Đanić M**, Milijašević B, Stankov K, Al-Salami H. The role of bile acids in pharmacotherapy. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 181-182.
 8. Pavlović N, Stankov K, Goločorbin-Kon S, Stanimirov B, **Đanić M**, Mikov M. Bile acids in the treatment of gastrointestinal inflammatory and malignant diseases. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 183-184.
 9. Stanimirov B, Stankov K, Pavlović N, **Đanić M**, Kojić V, Barjaktarović I, Mikov M. Bile acid-mediated modulation of doxorubicin pharmaco-dynamics in human breast adenocarcinoma cell line. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 185-186.
 10. Pavlović N, Stankov K, Goločorbin-Kon S, Stanimirov B, **Đanić M**, Lalić-Popović M, Mikov M. Anti-cholestatic activity of bile acids mediated by glutathione-dependent anti-oxidant system. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 186-188.
 11. **Đanić M**, Pavlović N, Stanimirov B, Lazarević S, Goločorbin-Kon S, Mikov M. In silico analysis of gliclazide metabolites produced by enzymatic activity of probiotic bacteria. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 242-243.
 12. Milošević N, Pavlović N, **Đanić M**, Goločorbin-Kon S, Stanimirov B, Stankov K, Mikov M. Antimetastatic potential of quercetin analogues with improved pharmacokinetic profile: pharmacoinformatic preliminary study. 14th Serbian congress of Pharmacologists and 4th Serbian congress of clinical pharmacology with international participation. Serbia, Novi Sad. September 18-21, 2019. pp. 251-252.
 13. **Đanić M**, Stanimirov B, Pavlović N, Lazarević S., Goločorbin-Kon S, Mikov M. Interakcije između gliklazida i probiotskih bakterija u in vitro uslovima. Simpozijum – X Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 24-25. novembar 2018. pp. 72-73.
 14. Mikov M, Goločorbin-Kon S, **Đanić M**, Vukmirović S, Milijašević B, Stankov K. Uticaj hrane na farmakokinetiku. Simpozijum – X Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 24-25. novembar 2018. pp. 34-35.
 15. Lazarević S, **Đanić M**, Tomas A, Pavlović N, Goločorbin-Kon S, Mikov M. 12-MKH: novi pristup u terapiji metaboličkog sindroma. Simpozijum – X Nedelja bolničke kliničke farmakologije.

- Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 24-25. novembar 2018. pp 70-71.
16. Mikov M, **Danić M**, Pavlović N, Stanimirov B, Goločorbin-Kon S, Stankov K, Al-Salami H. Nova perspektiva tretmana dijabetes mellitusa: mesto žučnih kiselina, probiotika i gliklazida kao mogući tretman dijabetesa tip 1. Simpozijum – IX Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 25-26. novembar 2017. pp. 32-33.
 17. **Danić M**, Stanimirov B, Pavlović N, Stankov K, Goločorbin-Kon S, Mikov M. Modifikacija raspodele simvastatina u prisistvu žučnih kiselina - in vitro studija. Simpozijum - VIII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 26-27. novembar 2016. pp. 78-79.
 18. **Danić M**, Pavlović N, Stanimirov B, Stankov K, Goločorbin-Kon S, Mikov M. Crevni mikrobiom - nova meta personalizovane medicine. Simpozijum - VIII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 26-27. novembar 2016. pp. 80-81.
 19. Pavlović N, Goločorbin-Kon S, Stankov K, **Danić M**, Stanimirov B, Lalić-Popović M, Mikov M. In silico modeli kao alternativa za životinjske in vivo sisteme u procesu razvoja lekova. Simpozijum - VIII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 26-27. novembar 2016. pp. 82-83.
 20. Pavlović N, **Danić M**, Stanimirov B, Lalić-Popović M, Stankov K, Goločorbin-Kon S, Mikov M. In silico pristup u pronalasku analoga karnozola sa poboljšanim farmakokinetiskim osobinama. Simpozijum - VIII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 26-27. novembar 2016. pp. 84-85.
 21. Mikov M, **Danić M**, Pavlović N, Goločorbin-Kon S. Značaj probiotika u savremenoj terapiji. Simpozijum – VII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2015. pp. 12-13.
 22. Goločorbin-Kon S, Pavlović N, **Danić M**, Mikov M. Falsifikovani lekovi. Simpozijum – VII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2015. pp. 26-27.
 23. **Danić M**, Pavlović N, Stanimirov B, Vukmirović S, Goločorbin-Kon S, Mikov M. 12-monoketoholna kiselina utiče na distribuciju simvastatina u oktanol-pufer sistemu. Simpozijum – VII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2015. pp. 60-61.
 24. Stanimirov B, Stankov K, Pavlović N, **Danić M**, Kojić V, Bogdanović G, Mikov M. Kvantitativna analiza citotoksične aktivnosti žučnih kiselina i doksorubicina u ćelijskoj liniji humanog adenokarcinoma dojke. Simpozijum – VII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2015. pp. 58-59.
 25. Pavlović N, Stankov K, **Danić M**, Stanimirov B, Goločorbin-Kon S, Mikov M. Uticaj henodeoksiholne kiseline na pokazatelje funkcije jetre u serumu kod pacova saolestazom. Simpozijum – VII Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2015. pp. 68-69.
 26. **Stojančević M**, Pavlović N, Goločorbin-Kon S, Stanimirov B, Bojić G, Mikov M. Žučne kiseline kao modifikatori prolaska lekova kroz biološke membrane. Simpozijum - VI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2014. pp. 78-79.
 27. Stankov K, Stanimirov B, Pavlović N, **Stojančević M**, Stepanov V, Mikov M. Stres endoplazmatskog retikuluma kao potencijalna meta novih antitumorskih terapijskih strategija. Simpozijum - VI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2014. pp. 72-73.
 28. Stanimirov B, Stankov K, Pavlović N, **Stojančević M**, Vukmirović S, Kojić V, Mikov M. Ursodeoksiholna kiselina redukuje doksorubicinom-indukovano oksidativno oštećenje hepatocita. Simpozijum - VI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2014. pp. 74-75.
 29. Pavlović N, Stankov K, Stanimirov B, **Stojančević M**, Kojić V, Bogdanović G, Mikov M. Različiti citotoksični efekti epimera žučnih kiselina na HT-29 ćelije karcinoma kolona. Simpozijum - VI Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 28-29. novembar 2014. pp. 76-77.

30. **Stojančević M**, Pavlović N, Stanimirov B, Bojić G, Mikov M. Uloga crevne mikroflore u metabolizmu lekova. Simpozijum - V Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 29. novembar - 1. decembar 2013. pp. 124-125.
31. Stanimirov B, Stankov K, Pavlović N, **Stojančević M**, Mikov M. Oksidativni stres i preventivne strategije u doksorubicinom-indukovanoj kardiomiopatiji. Simpozijum - V Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 29. novembar - 1. decembar 2013. pp. 52-53.
32. Pavlović N, Stankov K, Stanimirov B, **Stojančević M**, Mikov M. Epigenetska terapija karcinoma: sadašnji pristupi i buduće smernice. Simpozijum - V Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 29. novembar - 1. decembar 2013. pp. 108-109.
33. Bojić G, **Stojančević M**, Milošević V, Mikov M, Goločorbin-Kon S. Faecal bacteriotherapy - modern treatment of infection on gastrointestinal tract. Simpozijum - V Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 29. novembar - 1. decembar 2013. pp. 110-111
34. **Stojančević M**, Pavlović N, Stanimirov B, Stepanov V, Stankov K, Mikov M. Farnezoid X receptor kao potencijalna meta za terapiju inflamatorne bolesti creva. Simpozijum - IV Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar - 1. decembar 2012. pp. 76-77.
35. Pavlović N, **Stojančević M**, Stepanov V, Stanimirov B, Stankov K, Mikov M. Uticaj probiotika na metabolički sindrom. Simpozijum - IV Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar - 1. decembar 2012. pp. 74-75.
36. Stepanov V, Stanimirov B, Pavlović N, **Stojančević M**, Stankov K, Mikov M. Aktivacija TGR5 signalnog puta - obećavajuća terapijska meta u bolestima metabolizma glukoze i lipida. Simpozijum - IV Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar - 1. decembar 2012. pp. 70-71.
37. Stanimirov B, Stepanov V, **Stojančević M**, Pavlović N, Stankov K, Mikov M. Plejotropne uloge žučnih kiselina posredovane preko nuklearnog farnezoid X receptora. Simpozijum - IV Nedelja bolničke kliničke farmakologije. Beograd: Sekcija za kliničku farmakologiju Srpskog lekarskog društva, 30. novembar - 1. decembar 2012. pp. 78-79.
38. **Stojančević M**, Pavlović N, Stankov K, Mikov M. Farnezoid X receptor u inflamatornoj bolesti creva. Simpozijum - III nedelja bolničke kliničke farmakologije. Beograd: Srpsko lekarsko društvo Akademija medicinskih nauka, 17-19. novembar 2011. pp. 67-68.
39. Pavlović N, **Stojančević M**, Stankov K, Mikov M. Probiotici - mogućnost upotrebe u terapiji hiperholesterolemije kod ljudi. Simpozijum - III nedelja bolničke kliničke farmakologije. Beograd: Srpsko lekarsko društvo Akademija medicinskih nauka, 17-19. novembar 2011. pp. 77-78.

M71 - ODBRANJENA DOKTORSKA DISERTACIJA

1. **Đanić M**. Uticaj soli žučnih kiselina na prodor i metabolizam simvastatina u probiotskim bakterijama (doktorska disertacija). Medicinski fakultet, Univerzitet u Novom Sadu; 2016.